# US HIV Diagnosis Treatment Market

> US HIV Diagnosis Treatment Market Research Report By Diagnosis (ELISA Test, Saliva Tests, Viral Load Test, Western Blot, Others), By Treatment (Protease inhibitors (PIs), Non-nucleoside reverse transcriptase inhibitors (NNRTIs), Nucleoside or nucleotide reverse transcriptase inhibitors (NRTIs), Entry or fusion inhibitors, Integrase inhibitors, Others), By Region - Growth & Industry Forecast 2025 To 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 4.38%
- **2024:** $ 586.46 Million
- **2025:** $ 621.51 Million
- **2035:** $ 939.93 Million
- **Key Players:** AbbVie Inc (US), Gilead Sciences Inc (US), Bristol-Myers Squibb Company (US), Merck & Co Inc (US), Johnson & Johnson (US), ViiV Healthcare (US), Roche Holding AG (US), Thermo Fisher Scientific Inc (US), Abbott Laboratories (US)

**Report ID:** MRFR/Pharma/17469-CR · **Pages:** 100 · **Author:** Satyendra Maurya & Garvit Vyas · **Last Updated:** April 06, 2026

**URL:** https://www.marketresearchfuture.com/reports/us-hiv-diagnosis-treatment-market-19015

---

## Market Summary

## **US HIV Diagnosis Treatment Market Highlighted Trends & Dynamics**

The demand for HIV diagnosis and treatment in the United States has witnessed significant growth, driven by a combination of factors that reflect both the evolving nature of the epidemic and advancements in medical science. As of 2022, an estimated 1.2 million people in the U.S. were living with HIV, making it a pressing public health concern. The demand for HIV diagnosis services has been consistently rising due to increased awareness, regular testing campaigns, and the emphasis on early detection for effective management.

The market for HIV diagnosis in the U.S. has seen a surge in demand for rapid tests, enabling quicker and more convenient screening. The shift towards point-of-care testing and home testing kits has contributed to a more accessible and decentralized approach to diagnosis, catering to a wider demographic. These innovations not only address the demand for timely diagnosis but also play a crucial role in reaching underserved populations and those who might be hesitant to visit healthcare facilities. In tandem with the diagnosis market, the demand for HIV treatment has experienced notable growth, driven by advancements in antiretroviral therapy (ART).

The U.S. has been at the forefront of research and development in HIV treatment, witnessing the introduction of new and more effective drugs. The emphasis on personalized medicine and combination therapies has improved patient outcomes and reduced the side effects associated with earlier medications. Additionally, the awareness campaigns and public health initiatives have played a pivotal role in increasing demand for treatment services.

The 'Undetectable = Untransmittable' (U=U) campaign, which highlights the fact that individuals with an undetectable viral load cannot transmit the virus to their HIV-negative partners, has contributed to destigmatizing the condition and encouraging more people to seek treatment. This has not only increased demand for treatment but has also fostered a supportive environment for those living with HIV. Furthermore, the implementation of policies like the Affordable Care Act (ACA) has expanded access to healthcare services, including those related to HIV diagnosis and treatment.

The ACA has facilitated increased insurance coverage, making essential HIV-related services more affordable and accessible to a broader population. This has undoubtedly contributed to the growing demand for HIV healthcare services across the nation.

## Market Drivers

### Rising Prevalence of HIV

The US HIV Diagnosis Treatment Market Industry is experiencing growth due to the rising prevalence of HIV infections across the country. According to the Centers for Disease Control and Prevention (CDC), approximately 1.2 million people in the US are living with HIV, with around 14% unaware of their infection status. This alarming statistic underscores the necessity for enhanced diagnostic and treatment options. As awareness increases, more individuals seek testing and treatment, driving demand for innovative solutions. The market is likely to expand as healthcare providers focus on early diagnosis and effective treatment strategies, which are crucial in managing the disease and reducing transmission rates. Furthermore, the increasing number of new diagnoses each year necessitates a robust response from the healthcare system, thereby propelling the US HIV Diagnosis Treatment Market Industry forward.

### Growing Awareness and Education

The US HIV Diagnosis Treatment Market Industry is benefiting from a growing awareness and education surrounding HIV/AIDS. Public health campaigns and educational programs have significantly increased knowledge about HIV transmission, prevention, and treatment options. Organizations such as the CDC and various non-profits are actively working to destigmatize HIV testing and treatment, encouraging individuals to seek care. This heightened awareness is likely to lead to increased testing rates, which in turn drives demand for diagnostic and treatment services. Furthermore, educational initiatives targeting high-risk populations are essential in promoting early diagnosis and treatment adherence. As more individuals become informed about their health, the US HIV Diagnosis Treatment Market Industry is expected to see a positive impact, with more people engaging in preventive measures and seeking timely treatment.

### Emergence of Personalized Medicine

The emergence of [personalized medicine](https://www.marketresearchfuture.com/reports/personalized-medicine-market-2937) is reshaping the US HIV Diagnosis Treatment Market Industry. Tailoring treatment regimens to individual patient profiles, including genetic factors and drug resistance patterns, enhances the effectiveness of HIV therapies. This approach not only improves patient outcomes but also minimizes adverse effects, leading to higher treatment adherence rates. The increasing availability of pharmacogenomic testing allows healthcare providers to make informed decisions regarding the most suitable treatment options for their patients. As personalized medicine continues to gain traction, it is likely to drive innovation within the market, prompting the development of new therapies and diagnostic tools. The focus on individualized care aligns with broader trends in healthcare, emphasizing the importance of patient-centered approaches in managing chronic diseases like HIV.

### Government Initiatives and Funding

Government initiatives play a pivotal role in shaping the US HIV Diagnosis Treatment Market Industry. The federal government, through programs such as the Ryan White HIV/AIDS Program, allocates substantial funding to support HIV care and treatment services. In recent years, there has been a concerted effort to increase funding for HIV prevention and treatment programs, which has led to improved access to diagnostic services. The National HIV/AIDS Strategy aims to reduce new infections and improve health outcomes for those living with HIV, thereby fostering a supportive environment for market growth. Additionally, state-level initiatives often complement federal efforts, creating a comprehensive framework for addressing HIV in the US. This synergy between federal and state programs is likely to enhance the overall effectiveness of the US HIV Diagnosis Treatment Market Industry.

### Technological Innovations in Diagnostics

Technological advancements are significantly influencing the US HIV Diagnosis Treatment Market Industry. Innovations such as rapid testing kits, point-of-care testing, and home testing options have revolutionized the way HIV is diagnosed. These technologies not only facilitate quicker results but also enhance accessibility, particularly in underserved communities. The integration of artificial intelligence and machine learning in diagnostic processes is also emerging, potentially improving accuracy and efficiency. As these technologies continue to evolve, they are expected to drive market growth by making testing more convenient and widespread. The increasing adoption of telehealth services further complements these advancements, allowing patients to receive timely diagnoses and treatment recommendations remotely. Consequently, the US HIV Diagnosis Treatment Market Industry is poised for expansion as these innovations become more prevalent.

## Future Outlook

The US HIV Diagnosis Treatment Market is projected to grow at a 4.38% CAGR from 2025 to 2035, driven by advancements in diagnostic technologies, increased awareness, and supportive government policies.

**New opportunities:**

- Expansion of telehealth services for [remote patient monitoring](https://www.marketresearchfuture.com/reports/remote-patient-monitoring-market-10905) Development of rapid point-of-care testing kits Integration of AI-driven analytics for personalized treatment plans

By 2035, the market is expected to be robust, driven by innovation and increased accessibility.

## Segment Insights

### By Diagnosis: ELISA Test (Largest) vs. Viral Load Test (Fastest-Growing)

The US hiv diagnosis-treatment market showcases a diverse range of diagnostic tests, with the ELISA Test holding the largest market share due to its widespread adoption and proven reliability. Saliva Tests and Western Blot follow but capture smaller shares. The Viral Load Test, while currently smaller, is gaining traction due to its ability to provide critical insights into the progression of the disease, reflecting a growing preference towards more specific and dynamic testing methods in clinical settings.

Growth trends indicate a shift towards more advanced and precise testing methodologies, driven by increasing awareness and earlier detection initiatives. Key factors include advancements in technology, the need for rapid and accurate testing, and rising prevalence rates in at-risk populations. This evolution is pushing the market beyond traditional methods, facilitating a surge in interest for tests that also inform treatment efficacy, particularly the Viral Load Test.

ELISA Test: Dominant vs. Viral Load Test: Emerging

The ELISA Test remains the dominant force in the diagnostic segment, recognized for its efficacy in screening and diagnosis; it offers a high sensitivity rate and is the standard initial test for HIV. Its ability to process a large number of samples efficiently makes it particularly valuable in both clinical and screening settings. In contrast, the Viral Load Test, which measures the amount of HIV in a sample, is rapidly emerging. It is favored for monitoring treatment effectiveness and disease progression, thereby driving significant growth. The increasing reliance on viral load analysis for personalized treatment strategies positions it as the fastest-growing diagnostic method, appealing to healthcare providers and patients seeking comprehensive management of HIV.

### By Treatment: Nucleoside or nucleotide reverse transcriptase inhibitors (NRTIs) (Largest) vs. Integrase inhibitors (Fastest-Growing)

In the US hiv diagnosis-treatment market, the treatment segment exhibits a diverse range of drug classes, each contributing distinctly to the market landscape. Nucleoside or nucleotide reverse transcriptase inhibitors (NRTIs) hold the largest share of this segment, driven by their long-standing efficacy and established role in HIV therapy. In contrast, integrase inhibitors are experiencing rapid growth, appealing particularly due to their favorable side effect profiles and convenience of use compared to older classes.

The growth trends within the treatment segment are predominantly influenced by the continuous advancements in drug formulations and the increasing focus on personalized medicine. As newer therapies enter the market, they often provide better tolerability and efficacy, aiding treatment adherence among patients. Moreover, the growing population of individuals diagnosed with HIV further fuels demand for innovative treatment options, solidifying the position of integrase inhibitors as a rising star in this evolving landscape.

NRTIs (Dominant) vs. Integrase inhibitors (Emerging)

Nucleoside or nucleotide reverse transcriptase inhibitors (NRTIs) are foundational in HIV treatment, accounting for a substantial portion of the market share due to their long history and effectiveness in viral suppression. These classes of medications work by mimicking the building blocks of DNA, thereby hindering the virus's ability to replicate. On the other hand, integrase inhibitors represent an emerging class that is rapidly gaining traction. These medications inhibit the integrase enzyme vital for the viral replication cycle, offering patients simpler dosing regimens and favorable safety profiles. As both classes evolve, they play critical roles in treatment strategies, with NRTIs maintaining dominance while integrase inhibitors emerge as a compelling alternative.

### By Patient Demographics: Adults (Largest) vs. Adolescents (Fastest-Growing)

In the US HIV Diagnosis Treatment Market, adults constitute the largest demographic segment, reflecting a significant portion of the infected population. Adolescents, while numerically smaller, represent a rapidly rising cohort due to increasing awareness and testing initiatives targeted at younger populations. Together, these segments underscore the varied landscape of HIV treatment, emphasizing the need for tailored interventions that address distinct characteristics of each group. Growth trends indicate a substantial rise in adolescent diagnoses, attributed to heightened screening efforts in schools and community health programs. The adult segment, while established, continues to evolve with new treatment options and ongoing education. As public health initiatives foster understanding and reduce stigma, both demographics are likely to see shifts in treatment patterns and preferences, driving overall market dynamics forward.

Adults (Dominant) vs. Adolescents (Emerging)

Adults remain the dominant demographic in the US HIV Diagnosis Treatment Market, characterized by a more stable treatment landscape and established care protocols. This segment includes individuals aged 18 and older who have historically carried the highest prevalence rates. Conversely, the adolescent demographic is emerging rapidly, driven by a growing number of new infections and enhanced healthcare access. This cohort, which includes youths aged 13 to 17, is increasingly recognized for needing unique, age-appropriate care, leading to innovations in treatment approaches tailored for them. The dynamic between these segments illustrates the evolving nature of HIV healthcare, highlighting the importance of addressing the specific needs of both established and emerging groups.

### By Healthcare Setting: Hospitals (Largest) vs. Clinics (Fastest-Growing)

In the US HIV Diagnosis Treatment Market, hospitals maintain a dominant position, contributing significantly to the overall market share. They provide comprehensive treatment options and specialized care, making them indispensable in the management of HIV. However, clinics are rapidly emerging as vital players, adapting to patients' needs for accessibility and convenience. They generally offer a range of HIV services tailored to lower barriers for testing and treatment, which enhances their market relevance.

Hospitals (Dominant) vs. Clinics (Emerging)

Hospitals are the cornerstone of the US healthcare system for HIV treatment, equipped with advanced medical technology and specialist physicians. They not only provide urgent care but also have the infrastructure to support complex treatment regimens. Conversely, clinics represent the emerging segment by focusing on patient-centric care models, emphasizing accessibility and affordability. They often operate in communities to provide preventive services and ongoing care, which resonates with patients seeking low-barrier solutions. This combination of attributes positions hospitals as the dominant force, while clinics are expected to grow significantly as they adapt to changing patient demands.

### By Testing Frequency: Routine Screening (Largest) vs. High-risk Screening (Fastest-Growing)

In the US HIV Diagnosis Treatment Market, 'Routine Screening' holds a significant share, reflecting its widespread adoption in healthcare settings. This segment is favored for early detection and prevention strategies, emphasizing consistent testing among the general population. In contrast, 'High-risk Screening' is rapidly gaining traction, driven by targeted programs focusing on vulnerable groups, thereby marking it as a vital segment in the market landscape.

Routine Screening (Dominant) vs. High-risk Screening (Emerging)

Routine Screening remains the dominant player within the US HIV Diagnosis Treatment Market, characterized by its established protocols and routine implementation in health institutions. It benefits from broad healthcare policies promoting regular testing. Meanwhile, High-risk Screening is an emerging segment, tailored to identify HIV in populations with elevated exposure to the virus. This approach relies on innovative outreach strategies and personalized healthcare, creating a vital path to enhance awareness and reduce transmission rates among at-risk individuals.

## Competitive Benchmarking

The Hiv Diagnosis Treatment Market in the US is characterized by a dynamic competitive landscape, driven by innovation, strategic partnerships, and a focus on patient-centric solutions. Key players such as Gilead Sciences Inc (US), AbbVie Inc (US), and ViiV Healthcare (US) are at the forefront, each employing distinct strategies to enhance their market presence. Gilead Sciences Inc (US) emphasizes research and development, particularly in antiviral therapies, while AbbVie Inc (US) focuses on expanding its portfolio through strategic acquisitions and collaborations. ViiV Healthcare (US), a joint venture specializing in HIV treatments, prioritizes community engagement and access initiatives, which collectively shape a competitive environment that is increasingly focused on comprehensive care solutions.
The market structure appears moderately fragmented, with several players vying for market share through localized manufacturing and optimized supply chains. Companies are increasingly localizing their production to reduce costs and improve responsiveness to market demands. This strategy not only enhances supply chain efficiency but also allows for better alignment with regulatory requirements and patient needs, thereby strengthening their competitive positioning.
In December 2025, Gilead Sciences Inc (US) announced a partnership with a leading telehealth provider to enhance access to HIV testing and treatment services. This strategic move is significant as it leverages digital health solutions to reach underserved populations, potentially increasing patient engagement and adherence to treatment regimens. Such initiatives reflect a broader trend towards integrating technology into healthcare delivery, which is likely to reshape patient interactions in the coming years.
In November 2025, AbbVie Inc (US) launched a new HIV treatment regimen that combines two existing therapies into a single pill, aimed at simplifying treatment for patients. This innovation is crucial as it addresses adherence challenges faced by many patients, thereby improving health outcomes. The introduction of such combination therapies indicates a shift towards more patient-friendly solutions, which may enhance AbbVie's competitive edge in the market.
In October 2025, ViiV Healthcare (US) expanded its community outreach programs, focusing on education and prevention in high-risk populations. This initiative underscores the importance of addressing social determinants of health in HIV care, positioning ViiV as a leader in holistic patient support. By fostering community relationships, ViiV is likely to enhance its brand loyalty and market share in a competitive landscape that increasingly values patient engagement.
As of January 2026, current trends in the Hiv Diagnosis Treatment Market indicate a strong emphasis on digitalization, sustainability, and the integration of artificial intelligence in treatment protocols. Strategic alliances are becoming more prevalent, as companies recognize the value of collaborative efforts in enhancing service delivery and innovation. The competitive differentiation is expected to evolve, shifting from traditional price-based competition to a focus on technological advancements, innovative treatment solutions, and reliable supply chains. This transition may redefine market dynamics, compelling companies to prioritize research and development as well as patient-centric strategies.

## Report Scope

| MARKET SIZE 2024 | 586.46(USD Million) |
| --- | --- |
| MARKET SIZE 2025 | 621.51(USD Million) |
| MARKET SIZE 2035 | 939.93(USD Million) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 4.38% (2024 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Million |
| Key Companies Profiled | AbbVie Inc (US), Gilead Sciences Inc (US), Bristol-Myers Squibb Company (US), Merck & Co Inc (US), Johnson & Johnson (US), ViiV Healthcare (US), Roche Holding AG (US), Thermo Fisher Scientific Inc (US), Abbott Laboratories (US) |
| Segments Covered | Diagnosis Method, Treatment Type, Patient Demographics, Healthcare Setting, Testing Frequency |
| Key Market Opportunities | Integration of advanced diagnostic technologies enhances early detection and treatment adherence in the US Hiv Diagnosis Treatment Market. |
| Key Market Dynamics | Technological advancements and regulatory changes drive innovation in the US HIV diagnosis and treatment market. |
| Countries Covered | US |

## Frequently Asked Questions

**Q: What was the overall market valuation of the US HIV diagnosis-treatment market in 2024?**
A: The overall market valuation was $586.46 Million in 2024.

**Q: What is the projected market valuation for the US HIV diagnosis-treatment market by 2035?**
A: The projected valuation for 2035 is $1216.51 Million.

**Q: What is the expected CAGR for the US HIV diagnosis-treatment market during the forecast period 2025 - 2035?**
A: The expected CAGR during the forecast period 2025 - 2035 is 6.86%.

**Q: Which companies are considered key players in the US HIV diagnosis-treatment market?**
A: Key players include AbbVie, Gilead Sciences, Bristol-Myers Squibb, Roche, Johnson & Johnson, Merck & Co., ViiV Healthcare, AstraZeneca, and Sanofi.

**Q: What were the revenue ranges for ELISA tests in the US HIV diagnosis segment?**
A: The revenue range for ELISA tests was $200.0 Million to $400.0 Million.

**Q: How much revenue did saliva tests generate in the US HIV diagnosis segment?**
A: Saliva tests generated revenue between $100.0 Million and $200.0 Million.

**Q: What is the revenue range for NRTIs in the US HIV treatment segment?**
A: The revenue range for NRTIs was $150.0 Million to $300.0 Million.

**Q: What were the revenue figures for integrase inhibitors in the US HIV treatment segment?**
A: Integrase inhibitors generated revenue between $100.0 Million and $200.0 Million.

**Q: What is the revenue range for viral load tests in the US HIV diagnosis segment?**
A: The revenue range for viral load tests was $150.0 Million to $300.0 Million.

**Q: What were the revenue figures for protease inhibitors in the US HIV treatment segment?**
A: Protease inhibitors generated revenue between $80.0 Million and $160.0 Million.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/us-hiv-diagnosis-treatment-market-19015*